Zobrazeno 1 - 10
of 50
pro vyhledávání: '"35"'
Autor:
C. Veyrat-Follet, Hélène Fontaine, Ferry A.L.M. Eskens, M Hospitel, P. Tresca, L. van Doorn, D. Tosi, Véronique Diéras, Corina Oprea, A. van der Gaast
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 110(9), 2170-2177. Nature Publishing Group
British Journal of Cancer, 110(9), 2170-2177. Nature Publishing Group
Background: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. Methods: Ombrabulin (30-min infusion, day 1) followed by docet
Autor:
Desire' Pantalone, Virginia Rotella, P. Tonelli, A. Mercatelli, Pietro Pantaleo, Antonio Taddei, Costanza Paoletti, Bruno Neri, Elisa Giommoni, Raffaella Grifoni
Publikováno v:
British Journal of Cancer
The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxali
Autor:
Byoung Chul Cho, Joong Bae Ahn, Jae Kyung Roh, W. J. Roh, Sun Young Rha, Hyun Cheol Chung, Nae Choon Yoo, Hei Cheul Jeung
Publikováno v:
British Journal of Cancer
This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m−2, administered twice daily for 14 days ev
Publikováno v:
British Journal of Cancer
This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11) and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who ha
Autor:
Richard H. J. Begent, G. J. S. Rustin, L Holden, J Gaffan, Michael J. Seckl, D Short, E. S. Newlands, S. Fuller
Publikováno v:
British Journal of Cancer
The risk of chemotherapy-induced infertility in male and female germ cell tumour (GCT) survivors is unclear, but may correlate with cisplatin dose. Here, we examine a large series of GCT patients for the effect of chemotherapy on those attempting to
Autor:
Patrick Schöffski, K Weigang-Köhler, J. Van den Brande, Pierre Fumoleau, F Reinke, Jan H.M. Schellens, Jantien Wanders, Florence Duffaud, Jan B. Vermorken, Arnaud Roth, R F de Boer
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Vol. 88, No 5 (2003) pp. 648-53
British Journal of Cancer, Vol. 88, No 5 (2003) pp. 648-53
Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously. Oral
Autor:
M. Butcher, Peter F. M. Wrigley, Peter Johnson, S. Love, S. P. Joel, L. Squires, M. L. Slevin, M. R. Pandian
Publikováno v:
British Journal of Cancer
Levels of the tumour markers neurone specific enolase (NSE), lactate dehydrogenase (LDH), chromogranin A (ChrA) and carcinoembryonic antigen (CEA) were measured in serum taken at presentation and during treatment, remission and relapse from 154 patie
Autor:
Debu Tripathy, Ricardo H. Alvarez, Rashmi Krishna Murthy, Naoto T. Ueno, Carlos H. Barcenas, Jimin Wu, Jangsoon Lee, Richard Piekarz, Toshiaki Iwase, S. Jackson, Stacy L. Moulder, Sharon H. Giordano, Jeffrey A. Moscow, Abenaa M. Brewster, Vicente Valero, Darren W. Davis, Jie Willey, Nuhad K. Ibrahim, Yu Shen, Powel H. Brown, Bora Lim, Daniel J. Booser
Publikováno v:
British Journal of Cancer
Background Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically revers
Autor:
Davide Nicoli, Carmine Pinto, Francesco Iachetta, Raffaella Zamponi, Lorenzo Tofani, Alessandra Romagnani, Bruno Casali, Angela Damato, Maria Banzi, Enrico Farnetti, Candida Bonelli
Publikováno v:
British Journal of Cancer
Background Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide
Autor:
Salah-Eddin Al-Batran, Severin Daum, Michael Stahl, Justus Körfer, Dirk Behringer, Frank Kullmann, Horst Lindhofer, Volker Kunzmann, Maren Knödler, Florian Lordick, Michael Schenk, Ulrich Hacker, Jörg Trojan, Sebastian Schroll, Stefan Ibach
Publikováno v:
British Journal of Cancer
Background Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic c